IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 61.21

Change

+0.05 (+0.08)%

Market Cap

N/A

Volume

0.22M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-19 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.08 (+0.05%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

+0.14 (+0.20%)

USD 2.70B
FXH First Trust Health Care AlphaD..

+0.26 (+0.25%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

+0.87 (+1.05%)

USD 0.18B
IDNA iShares Genomics Immunology an..

+0.08 (+0.38%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.45 (+1.47%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.61 (+0.63%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.18 (+0.64%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.05 (+1.74%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.39 (+1.97%)

USD 6.67M

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

N/A

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.05% 67% D+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.05% 67% D+ 76% C+
Trailing 12 Months  
Capital Gain 0.07% 38% F 42% F
Dividend Return 1.19% 88% B+ 23% F
Total Return 1.25% 52% F 35% F
Trailing 5 Years  
Capital Gain 83.81% 86% B+ 56% F
Dividend Return 9.50% 74% C 16% F
Total Return 93.31% 86% B+ 48% F
Average Annual (5 Year Horizon)  
Capital Gain 5.71% 76% C+ 53% F
Dividend Return 6.72% 76% C+ 49% F
Total Return 1.01% 79% B- 24% F
Risk Return Profile  
Volatility (Standard Deviation) 18.37% 52% F 59% D-
Risk Adjusted Return 36.58% 71% C- 50% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike